Beyond sharing data, DQS aligns multiple data sources, including sponsors’ clinical trial management system data, public registries, and clinical trial databases, to provide a single, holistic, and ...

Jonathan Andrus, co-CEO of CRIO, explains how protocol-driven eSource templates and standardized data capture are improving ...

The emergence of AI and biosensors offers a chance to address inefficiencies in drug development.

If followed, clinical trial protocols established during the COVID-19 pandemic could allow more patients participate. The COVID-19 pandemic caused a major shift in the way that health care was ...

The COVID-19 pandemic is halting and slowing down clinical trials, and the Food and Drug Administration is offering guidelines to adjust to these new challenges. Clinical trials may slow, stop or ...

An international group of cancer researchers, led by the National Cancer Research Institute's (NCRI) Cellular Molecular Pathology Initiative (CMPath), has published guidance to address the variability ...

Over the past several years, the number of deviations and substantial amendments made to clinical trial protocols has increased notably, contributing to delays in drug development and rising costs for ...

Diversity in clinical trials matters for drug safety and efficacy—and for future medical advancements. Clinical trial ...

TARPON SPRINGS, Fla., June 2, 2025-- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a ...